DK3235812T3 - Deutererede derivater af ivacaftor - Google Patents
Deutererede derivater af ivacaftor Download PDFInfo
- Publication number
- DK3235812T3 DK3235812T3 DK17160386T DK17160386T DK3235812T3 DK 3235812 T3 DK3235812 T3 DK 3235812T3 DK 17160386 T DK17160386 T DK 17160386T DK 17160386 T DK17160386 T DK 17160386T DK 3235812 T3 DK3235812 T3 DK 3235812T3
- Authority
- DK
- Denmark
- Prior art keywords
- ivacaftor
- deuterated derivatives
- deuterated
- derivatives
- Prior art date
Links
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical class C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487497P | 2011-05-18 | 2011-05-18 | |
| EP12725197.3A EP2709986B1 (en) | 2011-05-18 | 2012-05-17 | Deuterated derivatives of ivacaftor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3235812T3 true DK3235812T3 (da) | 2019-11-25 |
Family
ID=46201810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17160386T DK3235812T3 (da) | 2011-05-18 | 2012-05-17 | Deutererede derivater af ivacaftor |
| DK12725197.3T DK2709986T3 (da) | 2011-05-18 | 2012-05-17 | Deutererede derivater af ivacaftor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12725197.3T DK2709986T3 (da) | 2011-05-18 | 2012-05-17 | Deutererede derivater af ivacaftor |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP2709986B1 (da) |
| JP (2) | JP6063455B2 (da) |
| AU (5) | AU2012255711B2 (da) |
| BR (1) | BR112013029240B1 (da) |
| CA (1) | CA2834574C (da) |
| CY (2) | CY1119090T1 (da) |
| DK (2) | DK3235812T3 (da) |
| EA (1) | EA028378B1 (da) |
| ES (2) | ES2758028T3 (da) |
| HR (2) | HRP20170754T1 (da) |
| HU (1) | HUE032771T2 (da) |
| LT (1) | LT2709986T (da) |
| ME (2) | ME02749B (da) |
| MX (1) | MX349159B (da) |
| PL (2) | PL2709986T3 (da) |
| PT (2) | PT3235812T (da) |
| RS (2) | RS59744B1 (da) |
| SI (2) | SI3235812T1 (da) |
| SM (2) | SMT201700302T1 (da) |
| WO (1) | WO2012158885A1 (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| JP6063455B2 (ja) * | 2011-05-18 | 2017-01-18 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたイバカフトルの誘導体 |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| EP2819670A1 (en) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| HK1206995A1 (en) * | 2012-04-06 | 2016-01-22 | The Uab Research Foundation | Methods for increasing cftr activity |
| JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| MY183582A (en) * | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| HK1249893A1 (zh) | 2015-03-31 | 2018-11-16 | Vertex Pharmaceuticals (Europe) Limited | 氘代vx-661 |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| UA124619C2 (uk) * | 2015-09-21 | 2021-10-20 | Вертекс Фармасьютікалз (Юроп) Лімітед | Введення дейтерованих підсилювачів cftr |
| HK1258473A1 (zh) | 2015-09-25 | 2019-11-15 | Vertex Pharmaceuticals (Europe) Limited | 氘代cftr增效剂 |
| BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CN110267948B (zh) | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| CA3082444A1 (en) | 2017-12-01 | 2019-06-06 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド | 重水素化されたｃｆｔｒ増強物質 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| CN114585628B (zh) | 2019-08-14 | 2024-03-26 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节因子的调节剂 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| LV15575A (lv) | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| WO2022076628A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373935A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023004074A (es) | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
| EP4225765A2 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225446A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225447A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| JP2025505577A (ja) | 2022-02-03 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態 |
| IL314449A (en) | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL315715A (en) | 2022-04-06 | 2024-11-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulation |
| EP4525858A1 (en) | 2022-05-16 | 2025-03-26 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3253977A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | SOLID FORMS OF MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025166342A1 (en) | 2024-02-04 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis |
| US20250248981A1 (en) | 2024-02-07 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CN1255185C (zh) | 2001-05-03 | 2006-05-10 | 弗·哈夫曼-拉罗切有限公司 | 无定形甲磺酸奈非那韦的药物剂型 |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| LT2502911T (lt) * | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| MX2007003731A (es) | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| AU2006331565A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in CFTR assays and methods therewith |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2021797B1 (en) | 2006-05-12 | 2011-11-23 | Vertex Pharmaceuticals, Inc. | Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| MX2010002692A (es) * | 2007-09-13 | 2010-06-01 | Concert Pharmaceuticals Inc | Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos. |
| HRP20180328T1 (hr) | 2008-08-13 | 2018-04-20 | Vertex Pharmaceuticals Inc. | FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| KR20110048571A (ko) * | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| JP6063455B2 (ja) * | 2011-05-18 | 2017-01-18 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたイバカフトルの誘導体 |
-
2012
- 2012-05-17 JP JP2014511524A patent/JP6063455B2/ja active Active
- 2012-05-17 ME MEP-2017-112A patent/ME02749B/me unknown
- 2012-05-17 PT PT171603863T patent/PT3235812T/pt unknown
- 2012-05-17 HU HUE12725197A patent/HUE032771T2/en unknown
- 2012-05-17 ES ES17160386T patent/ES2758028T3/es active Active
- 2012-05-17 BR BR112013029240-7A patent/BR112013029240B1/pt active IP Right Grant
- 2012-05-17 RS RS20191494A patent/RS59744B1/sr unknown
- 2012-05-17 AU AU2012255711A patent/AU2012255711B2/en active Active
- 2012-05-17 HR HRP20170754TT patent/HRP20170754T1/hr unknown
- 2012-05-17 LT LTEP12725197.3T patent/LT2709986T/lt unknown
- 2012-05-17 WO PCT/US2012/038297 patent/WO2012158885A1/en not_active Ceased
- 2012-05-17 ES ES12725197.3T patent/ES2628465T3/es active Active
- 2012-05-17 EP EP12725197.3A patent/EP2709986B1/en active Active
- 2012-05-17 MX MX2013013450A patent/MX349159B/es active IP Right Grant
- 2012-05-17 DK DK17160386T patent/DK3235812T3/da active
- 2012-05-17 SM SM20170302T patent/SMT201700302T1/it unknown
- 2012-05-17 SI SI201231694T patent/SI3235812T1/sl unknown
- 2012-05-17 SM SM20190679T patent/SMT201900679T1/it unknown
- 2012-05-17 PL PL12725197T patent/PL2709986T3/pl unknown
- 2012-05-17 EA EA201391615A patent/EA028378B1/ru unknown
- 2012-05-17 PL PL17160386T patent/PL3235812T3/pl unknown
- 2012-05-17 RS RS20170601A patent/RS56096B1/sr unknown
- 2012-05-17 SI SI201230988A patent/SI2709986T1/sl unknown
- 2012-05-17 ME MEP-2019-325A patent/ME03652B/me unknown
- 2012-05-17 PT PT127251973T patent/PT2709986T/pt unknown
- 2012-05-17 CA CA2834574A patent/CA2834574C/en active Active
- 2012-05-17 EP EP17160386.3A patent/EP3235812B1/en active Active
- 2012-05-17 DK DK12725197.3T patent/DK2709986T3/da active
-
2016
- 2016-12-16 JP JP2016243941A patent/JP2017078082A/ja active Pending
-
2017
- 2017-06-02 CY CY20171100584T patent/CY1119090T1/el unknown
- 2017-07-27 AU AU2017208313A patent/AU2017208313A1/en not_active Abandoned
-
2019
- 2019-08-28 AU AU2019222862A patent/AU2019222862B2/en active Active
- 2019-11-25 HR HRP20192114TT patent/HRP20192114T1/hr unknown
- 2019-12-04 CY CY20191101275T patent/CY1122498T1/el unknown
-
2021
- 2021-02-15 AU AU2021200970A patent/AU2021200970B2/en active Active
- 2021-06-08 AU AU2021203786A patent/AU2021203786B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3235812T3 (da) | Deutererede derivater af ivacaftor | |
| DK3725778T4 (da) | Formuleringer af enzalutamid | |
| PL3450434T3 (pl) | Deuterowane pochodne ruksolitynibu | |
| DK2771364T3 (da) | Fremstilling af heterodimere proteiner | |
| EP2663266C0 (en) | ENDOPROSTHESIS | |
| CO6890099A2 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| DK3156056T3 (da) | Farmaceutiske sammensætninger der består af sorbitanestere | |
| UY4115Q (es) | Reloj | |
| EP2673344A4 (en) | STABLE BIO OIL | |
| DK2733803T4 (da) | Sektion af kabelbakke | |
| BR112014013850A2 (pt) | conjunto de prateleiras | |
| IL231950B (en) | Aryl-quinoline derivatives | |
| DK3494993T3 (da) | Ny anvendelse af maltotriosyl-transferase | |
| EP2668926A4 (en) | STENT IMPLANT | |
| DK2800572T3 (da) | Sammensætning af ellagitannin-rige ekstrakter | |
| PT2790693T (pt) | Administração de estatinas sublinguais | |
| DK2692211T3 (da) | Lysdæmperstyring af vinkellysfordeling | |
| HUE036319T2 (hu) | 2-karboxamid-cikloamino-karbamidszármazékok szintézise | |
| DK2571843T3 (da) | Forbedret fremstilling af chalcon-derivater | |
| DK2731572T3 (da) | Forbedringer af indgivelsesanordninger | |
| DK2888228T3 (da) | Inhibitorer af CD40-TRAF6 interaktion | |
| DK2838850T3 (da) | Oprensning af titantetrachlorid | |
| DK2407155T3 (da) | Formuleringer af inecalcitol | |
| DK2928896T3 (da) | Fast form af dihydro-pyrido-oxazin-derivat | |
| DK2731573T3 (da) | Forbedringer af indgivelsesanordninger |